2013 FRAXA Investigators Meeting: Treatment Strategies for Fragile X
September 29-October 2, 2013
Southbridge Hotel and Conference Center, Southbridge, MA
We are pleased to announce that registration is open for the 2013 FRAXA Investigators Meeting. We expect another lively meeting with presentations of recent advances in the field of Fragile X research. This meeting, as with past ones, will provide ample opportunity for discussion, debate and collaboration.
Preliminary Meeting Outline
Presentation Preference Form
Gordon Conference in Fragile X and Autism-related Disorders
Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies. The Gordon conferences in Fragile X and Autsim are held in even years (2012, 2014, etc.) and FRAXA Investigators Meetings are planned bi-annually in 2013, 2015, etc.
June 1-6, 2014
Mount Snow Resort
West Dover, VT
Jennifer C. Darnell and
Michael R. Tranfaglia
Immediately preceeding each Gordon Research Conferences will be a bi-annual Gordon Research Seminar (GRS) on Fragile X and Autism. This is a forum for graduate students and post-docs to present and discuss their cutting edge research among peers and mentors. The small size and focus on young investigators provide an ideal interactive and unintimidating atmosphere.
The 2014 Gordon Research Seminar
May 31 - June 1, 2014
Mount Snow Resort
West Dover, VT
More details about the 2014 conferences at the Gordon Conferences website
Previous Meetings to advance research
2011 FRAXA Investigators Meeting: Pursuing Pathways to Treatment
The goal of the meeting was to further the mission of finding and implementing viable treatments for Fragile X. Over 150 scientists from a dozen countries attended. It was held
September 18-21 in Southbridge, MA.
Annual Fragile X Banbury Meetings
Fragile X Banbury meetings were established in 2000 at Cold Spring Harbor Laboratory
in New York, thanks to Nobel Laureate James D. Watson, who proposed them to stimulate
new research. The annual meetings from 2000 through 2005 were funded by a grant from
NIMH with additional help from NICHD; Co-Principal Investigators were William Greenough,
of the University of Illinois at Urbana-Champaign and Katie Clapp, of FRAXA. The meetings
run for two and a half days and are wonderfully intense, with people discussing Fragile
X from 8am until late in the evening.
In 2006, NIMH funded an additional five years of annual meetings through a grant awarded
to William Greenough (Univ. of Illinois), Elizabeth Berry-Kravis (Rush University), and Katie
Clapp (FRAXA Research Foundation). The 2008 meeting was organized by Eric Klann (Emory), Peter
Vanderklish (Scripps), in addition to W. Greenough, E. Berry-Kravis, and K. Clapp.
The 2005 meeting focused on identifying outcome measures which are needed to test potential
treatments. A number of practical measures have been validated in studies with human patients
and with animal models of Fragile X. These measures are being used in a number of labs to
test potentially therapeutic compounds.
The 2004 meeting was co-chaired by Will Spooren, a drug development scientist of Hoffman LaRoche,
and Bill Greenough. The focus was pharmacological treatments for Fragile X: which existing drugs
and experimental new compounds might be effective for treating Fragile X. Participants were
equally drawn from the pharmaceutical industry, representing seven different companies including
Novartis, Addex, Lilly,Merck, and Hoffman LaRoche, and the university-based basic research
community. Several collaborations between industry and university scientists were established
at the meeting.
FRAXA Investigators' Meeting
FRAXA sponsored a research meeting at Arden House in Harriman, NY, in July 2005.
Participants included Story Landis (Director, NINDS), Bill Greenough (University of Illinois),
David Nelson (Baylor College of Medicine), Tom Jongens (U Penn), Jennifer Darnell (Rockefeller),
Samie Jaffrey (Cornell), Miklos Toth (Cornell), Mark Bear (MIT), Holly Cline (CSHL), Walter
Kaufmann (Kennedy Krieger Institute), Eric Klann (Baylor), Yue Feng (Emory), Stephanie Ceman
(Illinois at Urbana Champaign), Justin Fallon (Brown), Gary Bassell (Albert Einstein), Ted Brown
(New York IBR), Carl Dobkin (New York IBR), Bob Denman (New York IBR), Bob Wong (SUNY Downstate),
Suzanne Zukin (Albert Einstein), Todd Sacktor (SUNY Downstate), Sam Schacher (Columbia), Henri
Tiedge (SUNY Downstate), Carolyn Beebe Smith (NIMH), Daniela Zarnescu (Emory).
At the Crossroads: Fragile X and Autism
In July 2004, scientists gathered at Salve Regina University in Newport, RI, to investigate
the common neurobiological pathways in Fragile X and autism spectrum disorders. The meeting
was sponsored by FRAXA and three of the National Institutes of Health (NIMH, NICHD and NINDS).
Researchers have found similarities in individuals with Fragile X and autism spectrum disorders.
At least 25% of people with Fragile X also have autism, and Fragile X is the most common known
genetic cause of autism.
Many people believe that there are shared genetic mechanisms between Fragile X and a subgroup
of individuals with autism. Further study of the Fragile X gene and genes it regulates could
offer important insights into the genetic basis of autism. But little research has been conducted
involving direct comparison between individuals with autism spectrum disorders, Fragile X, and
autism with Fragile X.
This workshop brought together leaders in these fields to develop future directions for research
that will accelerate progress on each of the disorders. We thank Steve Moldin of NIMH, Laura
Mamounas of NINDS, and Alice Kau of NICHD, the co-chairs, Dr. Dan Geschwind and Dr. Robert Wong,
and all the participants for an extraordinary meeting.